1. Home
  2. BCDA vs ZDAI Comparison

BCDA vs ZDAI Comparison

Compare BCDA & ZDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • ZDAI
  • Stock Information
  • Founded
  • BCDA N/A
  • ZDAI 2022
  • Country
  • BCDA United States
  • ZDAI Hong Kong
  • Employees
  • BCDA 17
  • ZDAI N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • ZDAI General Bldg Contractors - Nonresidential Bldgs
  • Sector
  • BCDA Health Care
  • ZDAI Consumer Discretionary
  • Exchange
  • BCDA Nasdaq
  • ZDAI Nasdaq
  • Market Cap
  • BCDA 13.7M
  • ZDAI 14.8M
  • IPO Year
  • BCDA N/A
  • ZDAI 2024
  • Fundamental
  • Price
  • BCDA $1.32
  • ZDAI $0.41
  • Analyst Decision
  • BCDA Strong Buy
  • ZDAI
  • Analyst Count
  • BCDA 1
  • ZDAI 0
  • Target Price
  • BCDA $25.00
  • ZDAI N/A
  • AVG Volume (30 Days)
  • BCDA 125.5K
  • ZDAI 2.2M
  • Earning Date
  • BCDA 11-12-2025
  • ZDAI 11-25-2025
  • Dividend Yield
  • BCDA N/A
  • ZDAI N/A
  • EPS Growth
  • BCDA N/A
  • ZDAI N/A
  • EPS
  • BCDA N/A
  • ZDAI N/A
  • Revenue
  • BCDA N/A
  • ZDAI $19,275,673.00
  • Revenue This Year
  • BCDA N/A
  • ZDAI N/A
  • Revenue Next Year
  • BCDA N/A
  • ZDAI N/A
  • P/E Ratio
  • BCDA N/A
  • ZDAI N/A
  • Revenue Growth
  • BCDA N/A
  • ZDAI 43.16
  • 52 Week Low
  • BCDA $1.00
  • ZDAI $0.37
  • 52 Week High
  • BCDA $3.20
  • ZDAI $107.36
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 43.26
  • ZDAI 36.36
  • Support Level
  • BCDA $1.25
  • ZDAI $0.45
  • Resistance Level
  • BCDA $1.45
  • ZDAI $0.42
  • Average True Range (ATR)
  • BCDA 0.08
  • ZDAI 0.04
  • MACD
  • BCDA 0.00
  • ZDAI -0.01
  • Stochastic Oscillator
  • BCDA 27.00
  • ZDAI 16.78

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About ZDAI Primega Group Holdings Limited Ordinary Shares

DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.

Share on Social Networks: